- Pharmaceutical companies
- Europe
- Russia
- Recordati
Recordati in Russia
E-mail: info@rusfic.com
Web: www.recordatirarediseases.com
Address:
-
RUSFIC LLC OOO ACCENT Ltd.
Krasnopresnenskaya Naberezhnaya 12 Entrance 7, offices 605-608, premises 2 123610, Moscow (Russian Federation)
Other Recordati's locations around the world
Europe
North America
Africa
Oceania
Clinical Trials sponsored by Recordati
-
RECORDATI GROUPRecruitingPost-Bariatric HypoglycemiaUnited States, Belgium, France, Italy, Spain, United Kingdom
-
RECORDATI GROUPRecruitingEndogenous Cushing's SyndromeUnited States, Germany, France
-
RECORDATI GROUPActive, not recruitingProstate Cancer | Neuroendocrine Tumors | Acromegaly | Cushing's Disease | Dumping Syndrome | Pituitary Tumors | Ectopic ACTH Secreting (EAS) Tumors | Melanoma Negative for bRAF | Melanoma Negative for nRASBelgium, Brazil, Bulgaria, Canada, France, Germany, Italy, Japan, Korea, Republic of, Thailand, Turkey, United States, Argentina, Greece, Hungary, India, Israel, Malaysia, Mexico, Netherlands, Peru, Poland, Portugal, Romania, Russian Federation and more
-
RECORDATI GROUPCompletedEssential HypertensionFrance
-
RECORDATI GROUPTerminatedLower Urinary Tract SymptomsSpain, United Kingdom, Italy, Germany, Poland
-
RECORDATI GROUPActive, not recruitingCushing's SyndromeUnited States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, China, Costa Rica, France, Germany, India, Italy, Japan, Korea, Republic of, Poland, Russian Federation, Spain, Thailand, Turkey
-
RECORDATI GROUPCompletedNeurogenic Detrusor OveractivityCzechia, France, Poland, Portugal
-
RECORDATI GROUPCompletedEvaluation of the Efficacy and Safety of Silodosin in the Treatment of the Signs and Symptoms of BPHBenign Prostatic HyperplasiaUnited Kingdom
-
RECORDATI GROUPRecruitingCushing's DiseaseItaly, Belgium, Bulgaria, Slovenia, United Kingdom
-
RECORDATI GROUPCompletedCushing's SyndromeFrance
About Recordati
Recordati è una multinazionale farmaceutica italiana fondata nel 1926 con sede a Milano. Sviluppa, produce e commercia prodotti farmaceutici o di chimica farmaceutica. Il 96,4% del fatturato è dato nel 2017 dal settore farmaceutico mentre il restante 3,6% dal settore chimico. Dal 2018 è controllata da CVC Capital Partners, fondo britannico di private equity, attraverso Rossini Investimenti. È quotata dal 1984 alla Borsa di Milano dove è presente nell'indice FTSE MIB.